AI Agent Operational Lift for A10 Clinical Solutions in Cary, North Carolina

Why AI matters at this scale

A10 Clinical Solutions operates in the sweet spot for AI disruption: a mid-market clinical research organization (CRO) with 201-500 employees and a dense network of trial sites. At this scale, the company faces the same complex, document-heavy workflows as global CROs but lacks their armies of data scientists. AI changes that equation. For a firm founded in 2005 and rooted in the Research Triangle, adopting AI isn't about replacing people—it's about making every clinical research associate (CRA) and site coordinator dramatically more productive. The clinical trial industry wastes billions annually on slow patient recruitment and manual data cleaning; mid-sized players who weaponize AI first will win sponsor contracts by promising faster cycle times and cleaner data.

The recruitment bottleneck

The single highest-leverage opportunity is AI-driven patient recruitment. Today, site coordinators manually screen electronic medical records against lengthy protocol criteria—a process that can take weeks per patient and still yields a 30% screen-failure rate. By deploying natural language processing (NLP) models trained on historical trial data and EMRs, A10 can pre-screen thousands of patients in hours and surface only those with a high probability of eligibility. This directly attacks the industry's dirty secret: nearly 80% of trials fail to meet enrollment timelines. For A10's pharma sponsors, every day saved in recruitment translates to earlier market access and millions in additional revenue. The ROI is immediate and measurable in reduced coordinator hours and faster site activation.

Smarter site selection and monitoring

A second high-impact area is predictive site selection. A10 has run hundreds of trials across its network, generating a proprietary dataset on which sites perform, which investigators enroll reliably, and which patient demographics convert. Feeding this into a machine learning model lets A10 recommend optimal site mixes for new protocols, avoiding the costly mistake of activating sites that under-enroll. Coupled with risk-based monitoring—where AI flags anomalous data patterns for targeted source data verification—A10 can reduce monitoring costs by 30-40% while improving data quality. For a mid-sized CRO, this operational leverage is a direct path to higher margins and more competitive bids.

Generative AI for regulatory docs

Finally, generative AI offers a quick win in regulatory document authoring. Drafting informed consent forms, protocols, and IRB submissions is labor-intensive and prone to inconsistency. Large language models, fine-tuned on A10's library of approved documents and regulatory guidelines, can produce first drafts in minutes, which experienced staff then review. This cuts document cycle times by 50% and ensures plain-language compliance that sponsors and ethics committees increasingly demand.

Deployment risks at this size band

Mid-market CROs face specific risks when adopting AI. First, HIPAA compliance and data privacy are non-negotiable; any patient data used for model training must be rigorously de-identified and governed. Second, regulatory acceptance requires that AI tools be validated and explainable—a "black box" that rejects patients or flags sites without clear reasoning will not pass FDA scrutiny. Third, change management is critical: site coordinators and CRAs may distrust AI recommendations, so a phased rollout with strong human-in-the-loop design is essential. Finally, vendor lock-in with SaaS AI platforms could erode A10's competitive differentiation if every CRO uses the same tool. The smart play is to layer custom models trained on A10's proprietary site data on top of commercial platforms, creating a defensible moat.